Novel EXO-T vaccine using polyclonal CD4+ T cells armed with HER2-specific exosomes for HER2-positive breast cancer
Rong Li,1,2 Rajni Chibbar,3 Jim Xiang1,2 1Cancer Research Cluster, Saskatchewan Cancer Agency, Saskatoon, SK, Canada; 2Department of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; 3Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon...
Main Authors: | Li R, Chibbar R, Xiang J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-10-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/novel-exo-t-vaccine-using-polyclonal-cd4-t-cells-armed-with-her2-speci-peer-reviewed-article-OTT |
Similar Items
-
Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro
by: Reza Hosseini-Ghatar, et al.
Published: (2017-09-01) -
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
by: Takuya Osada, et al.
Published: (2018-08-01) -
Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity
by: Lei Wang, et al.
Published: (2020-10-01) -
A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer
by: Costa R, et al.
Published: (2019-01-01) -
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
by: Andres Lopez-Albaitero, et al.
Published: (2017-03-01)